Edson Oliveira

3DT Holdings (United States) — United States

Medicine · Health Sciences

16h-index653citations60works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Mosquito-borne diseases and control(14), Viral Infections and Vectors(9), Malaria Research and Control(8), CAR-T cell therapy research(8), Monoclonal and Polyclonal Antibodies Research(5)

Publications60 total

202 CER-1236, an investigational T cell product targeting TIM-4 Ligand, exhibits sustained effector function and resistance to exhaustion
Regular and Young Investigator Award Abstracts·2025Open Access
AML-795: First-in-Human Study of Autologous Chimeric Engulfment Receptor T Cell CER-1236 Targeting TIM-4-L in Acute Myeloid Leukemia (CertainT-1)
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: AML-795 First-in-Human Study of Autologous Chimeric Engulfment Receptor T Cell CER-1236 Targeting TIM-4-L in Acute Myeloid Leukemia (CertainT-1)
Clinical Lymphoma Myeloma & Leukemia·2025
First-in-human study of autologous chimeric engulfment receptor T-cell CER-1236 targeting TIM-4-l in acute myeloid leukemia (CertainT-1).
Journal of Clinical Oncology·2025· 1 cited
363 TIM-4-L expression on ovarian cancer can be targeted by engineered chimeric engulfment receptor T cells without toxicity
Regular and Young Investigator Award Abstracts·2024Open Access
Data from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia
2024Open Access
Data from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia
2024· 1 citedOpen Access
Supplementary Data 1 from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia
2024Open Access
Supplementary Data 1 from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia
2024Open Access
Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia
Clinical Cancer Research·2024· 2 cited
Brief Review: Virtual Reality and Physical Exercise as Countermeasures of Coping the Space Missions
Health Nexus·2024· 2 citedOpen Access
Uma Proposta para Automatização de Avaliação de Usabilidade/UX
2023Open Access
Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia
2023Open Access
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation
Molecular Therapy·2023· 8 citedOpen Access
Intracellular Sequestration of the NKG2D Ligand MIC B by Species F Adenovirus
Viruses·2021· 4 citedOpen Access
Using machine learning to develop a novel COVID-19 Vulnerability Index (C19VI)
The Science of The Total Environment·2021· 4 citedOpen Access
Targeting Nsp9 as an anti-SARS-CoV-2 strategy
New Journal of Chemistry·2020· 14 cited
Using Machine Learning to Develop a Novel COVID-19 Vulnerability Index\n (C19VI)
arXiv (Cornell University)·2020Open Access
Fatal Dengue Cases Reveal Brain Injury and Viral Replication in Brain-Resident Cells Associated with the Local Production of Pro-Inflammatory Mediators
Viruses·2020· 19 citedOpen Access
Immune evasion by adenoviruses: a window into host–virus adaptation
FEBS Letters·2019· 40 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Brandon Cieniewicz(9), Ankit Bhatta(9), Hongxiu Ning(9), Marciano Viana Paes(8), José Pedro Lavrador(7), Abhishek Maiti(7), Carlos Alberto Basílio‐de‐Oliveira(6), Natália Gedeão Salomão(6), Bruno A. C. Horta(5), Tiago F. Póvoa(5), José Pimentel(5), Damoun Torabi(5), Mike Saxton(5), Alexander Arballo(5), Phanidhar Kukutla(5), Zhuo Yang(5), Maria Fate(5), Lawrence Corey(5), Daniel Corey(5), Simone M. Costa(4)